# A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs

> **NCT07343245** · PHASE1 · RECRUITING · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Healthy Adult

## Interventions

- **DRUG:** DW4421
- **DRUG:** DW4421-N1
- **DRUG:** DW4421-N2
- **DRUG:** DW4421-N3

## Key facts

- **NCT ID:** NCT07343245
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-02-22
- **Final completion:** 2026-06-17
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07343245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07343245, "A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07343245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*